Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03898791 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer
A Phase 1 study of Small-cell Lung Cancer, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 20
- Study locations
NCT03898791 is a Phase 1 study of Small-cell Lung Cancer that has completed, run by Eli Lilly and Company. The registered enrollment target is 48 participants, below the 232-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT03898791, a Phase 1 study of Small-cell Lung Cancer, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.
Conditions Studied
Interventions
- DRUG LY3295668 Erbumine
Study Locations (20)
Texas
- Texas Oncology Cancer Center - Austin
- Texas Oncology Fort Worth - Fort Worth
- University of Texas MD Anderson Cancer Center - Houston
- US Oncology - The Woodlands
- Tyler Cancer Center - Tyler
Other
- Grand Hopital de Charleroi-Site Notre-Dame - Charleroi
- Universitair Ziekenhuis Gent - Ghent
- Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg - Leuven
- AZ Delta - Roeselare
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Arkansas
- Highlands Oncology Group - Fayetteville
Colorado
- Rocky Mountain Cancer Center - Denver
Florida
- H Lee Moffitt Cancer Center - Tampa
Missouri
- Washington University Medical School - St Louis
New Hampshire
- Dartmouth Hitchcock Medical Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2019-07-16 |
| Est. Completion | 2021-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03898791
The ClinicalTrials.gov registry entry for NCT03898791 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 232-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (79% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which LY3295668 Erbumine is the first listed.
NCT03898791 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Texas, Other, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03898791 about?
NCT03898791 is a clinical study titled "A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer". The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.
What is the current status of trial NCT03898791?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2019-07-16. Estimated completion is 2021-03-30.
What conditions does trial NCT03898791 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer.
What interventions are being tested in trial NCT03898791?
The interventions under investigation include: LY3295668 Erbumine (DRUG).
Who is sponsoring clinical trial NCT03898791?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03898791 being conducted?
This trial has 20 study locations across Arkansas, Colorado, Florida, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.